chevron_leftBack
As of 24 April 2025, Santhera Pharmaceuticals Holding AG has a market cap of $221.74M USD, ranking #16845 globally and #182 in Switzerland. It ranks #1673 in the Healthcare sector, and #466 in the Biotechnology industry.
Key Stats
Market Cap
$221.74MUSD
183.14M CHF
Enterprise Value
$233.71MUSD
193.02M CHF
Revenue (TTM)
$137.53MUSD
113.59M CHF
EBITDA (TTM)
$69.35MUSD
57.27M CHF
Net Income (TTM)
$76.1MUSD
62.86M CHF
EBITDA Margin
50%
Profit Margin
55%
PE Ratio
2.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Dario Eklund
open_in_new
Employees
44
Founded
2004
Website
santhera.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.7% | -1% | -2.8% | -13% | 62% | 53% |
Upcoming Earnings
Earnings Date
Tue, Apr 29
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SANN
ISIN: CH1276028821
Shares Out.:
Shares Outstanding:
12.595M1
Shares Float:
9.798M2
|
14.44 CHF | |
|
0QN1
ISIN: CH1276028821
|
14.58 CHF | |
|
SPHDF
ISIN: CH1276028821
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
16.45 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
